{
    "clinical_study": {
        "@rank": "48643", 
        "arm_group": [
            {
                "arm_group_label": "ferric carboxymaltose", 
                "arm_group_type": "Active Comparator", 
                "description": "ferric carboxymaltose"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary efficacy objective of this study is to evaluate the effect of ferric\n      carboxymaltose on mitochondrial gene activation pattern after 12 weeks of treatment."
        }, 
        "brief_title": "Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose", 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Anemia, Iron-Deficiency"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with chronic heart failure of New York Heart Association Class II or III, a\n             left ventricular ejection fraction of \u2264 40% for patients in NYHA class II or \u2264 45%\n             for patients in NYHA class III, a hemoglobin level at the screening visit between\n             9.5-13.5 g/dl, and iron deficiency, which is defined as serum ferritin level <\n             100\u00b5g/l or between 100 and 299 \u00b5g/l, when transferring saturation is < 20%.\n\n          -  Age \u226518 years\n\n          -  Obtained informed consent\n\n          -  Stable pharmacological therapy during the last 4 weeks (with the exception of\n             diuretics)\n\n        Exclusion Criteria:\n\n          -  Hemochromatosis, iron overload, defined as TSAT > 45%\n\n          -  Known hypersensitivity to Ferinject\u00ae.\n\n          -  Known active infection, CRP>20 mg/L, clinically significant bleeding, active\n             malignancy.\n\n          -  Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate\n             transaminase (AST) above three times the upper limit of the normal range.\n\n          -  Immunosuppressive therapy or renal dialysis (current or planned within the next 6\n             months).\n\n          -  History of erythropoietin, i. v. or oral iron therapy, and blood transfusion in\n             previous 12 weeks and/or such therapy planned within the next 6 months.\n\n          -  Unstable angina pectoris as judged by the investigator, clinically significant\n             uncorrected valvular disease or left ventricular outflow obstruction, obstructive\n             cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly\n             controlled symptomatic brady- or tachyarrhythmias.\n\n          -  Acute myocardial infarction or acute coronary syndrome, transient ischemic attack or\n             stroke within the last 3 months.\n\n          -  Coronary-artery bypass graft, percutaneous intervention (e.g. cardiac,\n             cerebrovascular, aortic; diagnostic catheters are allowed) or major surgery,\n             including thoracic and cardiac surgery, within the last 3 months.\n\n          -  Participation in a CHF training program.\n\n          -  Known HIV/AIDS.\n\n          -  Inability to fully comprehend and/or perform study procedures in the investigator's\n             opinion.\n\n          -  Vitamin B12 and/or serum folate deficiency according to the laboratory (re-screening\n             is possible after substitution therapy).\n\n          -  Pregnancy or lactation.\n\n          -  Participation in another clinical trial within previous 30 days and/or anticipated\n             participation in another trial during this study.\n\n          -  Anticoagulation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01978028", 
            "org_study_id": "Vifor-HF"
        }, 
        "intervention": [
            {
                "arm_group_label": "ferric carboxymaltose", 
                "intervention_name": "ferric carboxymaltose", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ferric Compounds"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "heart failure", 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich, Division of Cardiology"
            }, 
            "investigator": {
                "last_name": "Frank Enseleit, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "Differential Gene Expression in Patients With Heart Failure and Iron Deficiency - Effects of Ferric Carboxymaltose", 
        "overall_contact": {
            "email": "silviya.cantatore@usz.ch", 
            "last_name": "Silviya Cantatore", 
            "phone": "+41 44 255 2280"
        }, 
        "overall_contact_backup": {
            "email": "frank.enseleit@usz.ch", 
            "last_name": "Frank Enseleit, MD"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Devision of Cardiology", 
            "last_name": "Frank Enseleit, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary efficacy objective of this study is to evaluate the effect of ferric carboxymaltose on mitochondrial gene activation pattern after 12 weeks of treatment", 
            "measure": "The primary efficacy objective of this study is to evaluate the effect of ferric carboxymaltose on mitochondrial gene activation pattern after 12 weeks of treatment", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01978028"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}